Prof. Liu Zhibo's team from Peking University (PKU)'s College of Chemistry and Molecular Engineering, along with collaborators, recently published a paper titled "Covalent targeted radioligands potentiate radionuclide therapy" ...
Jun 4, 2024
0
0
Using artificial intelligence (AI), breast radiologists in Denmark have improved breast cancer screening performance and reduced the rate of false-positive findings. Results of the study were published in Radiology.
Jun 4, 2024
0
1
People battling advanced esophageal cancers should get doses of chemotherapy both before and after tumor-removing surgeries, a new study suggests.
Jun 4, 2024
0
0
From the traditional cigarette to the modern electronic cigarette, from the communal hookah to the discreet pinch of smokeless tobacco, each has proven to be detrimental to a person's health. Dr. Jon Ebbert, medical director ...
Jun 4, 2024
0
2
From an economic perspective, first-line prostate-specific antigen (PSA) testing is favored over biparametric magnetic resonance imaging (bpMRI) for prostate cancer screening, mainly due to false-positive results and overdiagnosis, ...
Jun 4, 2024
0
0
Black patients with early-stage breast cancer who were treated with docetaxel chemotherapy every 3 weeks had less drug-induced peripheral neuropathy and significantly fewer dose reductions compared to those who received weekly ...
Jun 4, 2024
0
0
Fanconi anemia (FA) is a rare hereditary cancer predisposition disease characterized by bone marrow failure as well as endocrine and physical abnormalities. A key clinical feature in those affected is a high risk of cancer. ...
Jun 3, 2024
0
1
Every year, several thousand cancer patients in Sweden risk receiving too little pain relief in the end of life, as the health care system fails to detect that the patients are suffering from pain. When patients cannot verbalize ...
Jun 3, 2024
0
0
A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown.
Jun 3, 2024
0
3
Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with a manageable safety profile and promising antitumour activity, especially in patients with metastatic cutaneous ...
Jun 3, 2024
0
0
